To assess a potential beneficial effect of tamoxifen supplementation in the mouse model of RYR1-related CNM, we compared untreated and tamoxifen-treated Ryr1TM/indel mice with untreated and tamoxifen-treated wild-type (WT) mice. Here, RYR1 is linked to centronuclear myopathy.